目的：探讨细胞分裂周期蛋白6（CDC6）在肝细胞癌（HCC）中的表达及其临床意义。方法：分别用qRT-PCR、Western blot和免疫组化法检测85例手术切除的HCC及对应癌旁组织标本中CDC6 mRNA及蛋白的表达，分析CDC6的表达与HCC患者临床病理因素及预后关系。结果：HCC组织中CDC6的mRNA与蛋白表达水平均高于对应癌旁组织，qRT-PCR结果定量分析显示差异有统计学意义（P<0.05）；CDC6表达与肿瘤大小、临床分期、分化程度及卫星结节有关（均P<0.05）；CDC6高表达的患者无瘤生存时间和总生存时间均低于CDC6低表达患者（均P<0.05）；单因素与多因素分析显示，CDC6是影响HCC患者无瘤生存率（HR=1.089，95% CI=0.986~1.186，P=0.033）及总生存率（HR=2.441，95% CI=1.128~3.652，P=0.012）的独立危险因子。结论：CDC6在HCC组织中高表达并与恶性临床病理特征及不良预后密切相关，CDC6可能参与HCC发生及进展，并可作为判断肿瘤复发及预后评价的重要指标。
Expression of cell division cycle 6 in hepatocellular carcinoma and its clinical significance
Objective: To investigate the expression of cell division cycle 6 (CDC6) in hepatocellular carcinoma (HCC) and its clinical significance. Methods: The mRNA and protein expressions of CDC6 in 85 surgical specimens of HCC tissue and matched adjacent tissue were determined by qRT-PCR, Western blot analysis and immunohistochemical staining, respectively. The relations of CDC6 expression with clinicopathologic characteristics and prognosis of HCC patients were analyzed. Results: Both mRNA and protein expression levels of CDC6 were increased in HCC tissue compared with adjacent tissue, and quantitative analysis of qRT-PCR results showed that the difference had statistical significance (P<0.05). The CDC6 expression was significantly related to tumor size, clinical stage, degree of differentiation and satellite lesions (all P<0.05). Both tumor-free survival rate and overall survival rate in patients with high CDC6 expression were significantly lower than those in patients with low CDC6 expression (both P<0.05), and both univariate and multivariate analyses showed that CDC6 was an independently risk factor for tumor-free survival rate (HR=1.089, 95% CI=0.986–1.186, P=0.033) and overall survival rate (HR=2.441, 95% CI=1.128–3.652, P=0.012) in HCC patients. Conclusion: CDC6 is highly expressed in HCC tissue, and is closely related to malignant clinicopathologic features and poor prognosis. CDC6 may contribute to the occurrence and development of HCC, and may be used as an index for estimating tumor recurrence and outcomes.